Research aids nasal drug delivery

RMIT University researchers have developed computer models to design more effective nasal sprays to provide alternate drug delivery to needles or pills.

The models explore deep into the human respiratory airway and focus on particle inhalation, allowing researchers to understand how particles move through the and where they deposit.

The models allow for powerful visualisation and reproduction of these particle flows and deposits.

Professor Jiyuan Tu, Deputy Head of Research and Innovation at RMIT's School of Aerospace, Mechanical and Manufacturing Engineering, is working on the project with the University's Health Innovations Research Institute.

The Federal Government's Australian Research Council has provided more than $1 million to support the work, which also involves collaboration with two US universities - Purdue and Clarkson - and the China National Nanoscience Centre.

Professor Tu, who is working with Dr Kiao Inthavong, a postdoctoral research fellow in his school, said the models enabled researchers to gain a better understanding of the toxicology and therapeutic effects of improved devices.

"We are using what's called (CFD)," he said.

"We have developed sophisticated models of the real respiratory airway from medical imaging techniques (CT and MRI) that includes the oral and nasal cavity, larynx, pharynx, trachea and the upper regions of the lung airway.

"These areas of the respiratory airway are capable of determining how and where the inhaled particles and gases will move and eventually deposit on to the respiratory walls.

"This new technology will significantly assist new findings in biomedical and health research."

Professor Tu said CFD models also allowed insight into determining the health risks and outcomes of exposure to and gases.

"These are sometimes difficult to determine using live humans or where invasive experimental techniques are involved," he said.

"For example, the models have tracked asbestos fibres as they enter the nasal cavity and eventually reach the deep lung regions causing lung complications such as mesothelioma."

Professor Tu said the new technology also provided powerful visualisation tools such as vector and contour plots, useful for conveying information such as the air/particle flow dynamics and its behaviour to non-health practitioners.

"For example, doctors can explain the effects of surgical procedures to the patient and family members, or engineers can develop optimised designs of room ventilation," he said.

"These studies of particle inhalation in human respiratory airways are also important for air quality - especially pollution, including dust and smoke - occupational health, dealing with bio-terrorist attacks and infectious disease outbreaks."

RMIT research projects in the emerging field have also involved industry, including the Hastie Group, D&E Air Conditioning, Airlinx and Woodwork Innovation.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments